Anti cytokine therapy of secondarily-progressing multiple sclerosis (ms)

Е. I. Gusev; Гусев Е. И.; Т. L. Demina; Демина Т. Л.; А. N. Boiko; Бойко А. Н.; А. V. Buglak; Буглак А. В.; I. А. Belyaeva; Беляева И. А.; N. F. Smirnova; Смирнова Н. Ф.; Т. G. Alekseeva; Алексеева Т. Г.; М. V. Pashchenkov; Пащенков М. В.; В. Skurkovich; Скуркович Б.; D. Kelly; Келли Д.; S. V. Skurkovic; Скуркович С. В.

doi:10.17816/nb79894

Anti cytokine therapy of secondarily-progressing multiple sclerosis (ms)

Authors: Gusev Е.I.¹^,2, Demina Т.L.³^,2, Boiko А.N.¹^,2, Buglak А.V.¹^,2, Belyaeva I.А.¹^,2, Smirnova N.F.¹^,2, Alekseeva Т.G.¹^,2, Pashchenkov М.V.¹^,2, Skurkovich В.¹^,2, Kelly D.¹^,2, Skurkovic S.V.¹^,2
Affiliations:
1. Russian State Medical University
2. ABC Labs
3. Российский государственный медицинский университет
Issue: Vol XXIX, No 1-2 (1997)
Pages: 55-58
Section: Articles
URL: https://journals.rcsi.science/1027-4898/article/view/79894
DOI: https://doi.org/10.17816/nb79894
ID: 79894

Cite item

Full Text

Abstract
Full Text
About the authors
References
Statistics

Abstract

For treating active forms of secondarily-progressing multiple sclerosis a preliminary clinical trial was performed by two courses: antibody-to-cytokine course (γINT, αINT and TNFα) and cyclosporin А-course (sandimmun). Data of preliminary test of antibodies to cytokines evidence to possibility of performing further clinical trials "antibodies to γINT and to TNFα (to a lesser degree)" during active forms of progressive MS. Were obtained the results, evidencing to a possible use of sandimmun in constantly progressive forms of secondarily progressing disease, when favourable clinical effect coincided with supression of cytokine IL-2 production and lowering of activeness of immunocytes.

Keywords

Neurological archive of Bekhterev

Full Text

##article.viewOnOriginalSite##

References

Гусев Е.И., Демина Т.Л., Бойко А.Н., Татаринова М.Ю. // Журн. невропатол. и психиатр.—1992.—№ 2.—С. 14—18.
Arnason B.G.W., Reder А.Т. // Clin. Neuropharmacol.— 1994—Vol.17 .—P.495—547.
Goodkin D.E. // West J. Med.—1994.—Vol.161.— P.292—298.
Gusev E.I., Demina T.L., Boiko A.N., Pinegin B.V. // J. Neurol.—1994.—Vol.241—P.500—510.
Gusev E.I., Demina T.L., Boiko A.N., Favorova 0.0. In: Milonas I (ed). Proceedings of the 10th ECTRIMS Congress.—University Studio Press, Thessaloniki, Greece, 1995.—P.201—203.
IFNB Multiple Sclerosis Study Group, the University of British Columbia, MS/MRI Analisis Group. Interferon betalb in the treatment of MS: final outcome of the randomized controlled trial.—Neurology.—1995.—Vol.45.—P.1277—1285.
Jacobs L., Cookfair D.L., Rudick R.A. et al. // Ann. Neurol.—1996.—Vol.39—P.285—294.
Kahan B.D. // J. Med.—1989.—Vol.321.—P.1725—1739.
Khoury S.J., Weiner H.L., Hafler D.A. In: Cook S (ed). Handbook of multiple sclerosis.—N.-Y., 1990.—P.129—150.
Kirk J. // J.Neuroimmunol.—1991.—Vol.32.—P.87—94.
McFarlin D.E. // Ann. Allergy.—1990.—Vol.64.— P.433—444.
Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial.—Ann. Neurol.—1990.—Vol.27.—P.591—605.
Poser C.M., Paty D.W., Scheinberg L. et al. // Ann. Neurol.— Vol. 13.—P.227—231.
Ruddle N.H., Beyman C.M., McGrath M.L. et al. // J. Exp. Med. —1990.—Vol. 172.—P. 1193—1200.
Selmaj K., Rain C.S. // Ann. Neurol.—1991—Vol.30.- P.694—700.
The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis // Lancet.— 1991.—Vol.337.—P.441—446.
Weiner H.L., Ellison G.W. // Arch. Neurol.—1983.— Vol.40.—P.704—710.
Whitaker LN. // Ann. Neurol.—1994.—Vol.36.- P.103—107.

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Anti cytokine therapy of secondarily-progressing multiple sclerosis (ms)

Full Text

Abstract

Keywords

Full Text

About the authors

References

This website uses cookies